市場調査レポート

商品コード

1491722

人工多能性幹細胞製造の市場規模、シェア、成長分析、細胞タイプ別、プロセス別、ワークフロー別、製品タイプ別、用途別、エンドユーザー別- 産業予測、2024-2031年

Induced Pluripotent Stem Cells Production Market Size, Share, Growth Analysis, By Cell type, By Process, By Workflow, By Product, By Application, By End-user - Industry Forecast 2024-2031

出版日: 2024年06月02日 | 発行: SkyQuest

| ページ情報: 英文 219 Pages | 納期: 3～5営業日

価格

PDF & Excel (Single User License)

USD 5,300 811,748円

レポートPDF・Excelを1 名様のみがご利用頂けるライセンスです。PDF・Excell内のテキスト等のコピーは可能です。PDF・Excelの印刷は可能ですが、印刷したもののご利用はPDF・Excelのご利用範囲に準拠します

PDF & Excel (Multiple User License)

USD 6,200 949,592円

レポートPDF・Excel2-5名様までがご利用頂けるライセンスです。PDF・Excel内のテキスト等のコピーは可能です。PDF・Excelの印刷は可能ですが、印刷したもののご利用はPDF・Excelのご利用範囲に準拠します。

PDF & Excel (Enterprise License)

USD 7,100 1,087,436円

レポートPDF・Excelを同一企業に所属の全世界の方にご使用頂けるライセンスです。PDF・Excel内のテキスト等のコピーは可能です。PDF・Excelの印刷は可能ですが、印刷したもののご利用はPDF・Excelのご利用範囲に準拠します。

価格表記: USDを日本円(税抜)に換算

本日の銀行送金レート: 1USD=153.16円

全表示
概要
目次

概要

サンプル依頼リストに入れる

人工多能性幹細胞製造の世界市場規模は、2022年に12億2,000万米ドルと評価され、2023年の13億5,000万米ドルから2031年には30億米ドルに成長し、予測期間中（2024-2031年）のCAGRは10.5％で成長する見通しです。

人工多能性幹細胞（iPSC）製造の世界市場は、再生医療と細胞治療の分野で急速な成長と革新を遂げています。成体細胞から誘導され、多能性状態に再プログラムされたiPSCは、個別化治療の選択肢や疾患モデル化に大きな可能性を提供します。この成長は、創薬から様々な病態の治療まで、iPSCの多様な応用に対する認識の高まりに後押しされています。スケーラビリティと費用対効果を保証する効率的なiPSC生産法を開発するため、研究者やバイオテクノロジー企業による取り組みが進行中であり、学界、産業界、ヘルスケア部門の協力によって促進されています。しかし、厳格な規制基準や倫理的配慮は、iPSCの製造方法を形成する上で重要な役割を果たしており、標準化されたプロトコールや安全対策の重要性が強調されています。世界のヘルスケア情勢が進化するにつれ、iPSC製造市場はさらなる拡大が見込まれ、画期的な医療の進歩や治療介入への道筋が期待されます。

市場概要
北米
- 米国
- カナダ
欧州
- ドイツ
- スペイン
- フランス
- 英国
- イタリア
- その他欧州地域
アジア太平洋地域
- 中国
- インド
- 日本
- 韓国
- その他アジア太平洋地域
ラテンアメリカ
- ブラジル
- その他ラテンアメリカ地域
中東・アフリカ（MEA）
- GCC諸国
- 南アフリカ
- その他中東・アフリカ地域

競合情勢

上位5社の比較
主要企業の市場ポジショニング（2023年）
主な市場企業が採用した戦略
市場における最近の活動
主要企業の市場シェア（2023年）

主要企業プロファイル

Axl Bioscience Ltd.（UK）
Cynata Therapeutics Limited（UK）
Evotec SE（Germany）
Fate Therapeutics, Inc.（US）
FUJIFILM Cellular Dynamics, Inc.（US）
Ncardia（Belgium）
Pluricell Biotech（Spain）
REPROCELL USA, Inc.（US）
Sumitomo Dainippon Pharma Co., Ltd.（Japan）
Takara Bio, Inc.（Japan）
Thermo Fisher Scientific, Inc.（US）
ViaCyte, Inc.（US）

Product Code: SQMIG35H2225

Global Induced Pluripotent Stem Cells Production Market size was valued at USD 1.22 billion in 2022 and is poised to grow from USD 1.35 billion in 2023 to USD 3 billion by 2031, growing at a CAGR of 10.5% during the forecast period (2024-2031).

The global market for induced pluripotent stem cell (iPSC) manufacturing is experiencing rapid growth and innovation within the field of regenerative medicine and cellular therapy. Derived from adult cells and reprogrammed to a pluripotent state, iPSCs offer significant potential for personalized treatment options and disease modeling. This growth is fueled by increasing awareness of iPSCs' diverse applications, spanning from drug discovery to treating various medical conditions. Efforts are underway by researchers and biotech firms to develop efficient iPSC production methods that ensure scalability and cost-effectiveness, facilitated by collaborations across academia, industry, and healthcare sectors. However, stringent regulatory standards and ethical considerations play a crucial role in shaping iPSC manufacturing practices, emphasizing the importance of standardized protocols and safety measures. As the global healthcare landscape evolves, the iPSC manufacturing market is poised for further expansion, promising avenues for groundbreaking medical advances and therapeutic interventions.

Top-down and bottom-up approaches were used to estimate and validate the size of the Global Induced Pluripotent Stem Cells Production Market and to estimate the size of various other dependent submarkets. The research methodology used to estimate the market size includes the following details: The key players in the market were identified through secondary research, and their market shares in the respective regions were determined through primary and secondary research. This entire procedure includes the study of the annual and financial reports of the top market players and extensive interviews for key insights from industry leaders such as CEOs, VPs, directors, and marketing executives. All percentage shares split, and breakdowns were determined using secondary sources and verified through Primary sources. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data.

Global Induced Pluripotent Stem Cells Production Market Segmental Analysis

The induced pluripotent stem cells production market is segmented on the basis of cell type, process, workflow, product, application, end-use and region. Based on cell type, the market is segmented into Hepatocytes, Fibroblasts, Keratinocytes, Neurons and Others. Based on the process, the market is segmented into Manual iPSC Production Process and Automated iPSC Production Process. Based on workflow, the market is segmented into Reprogramming, Cell Culture, Cell Characterization/Analysis, Engineering, and Others. Based on product, the market is segmented into Instruments/ Devices, Automated Platforms, Consumables & Kits (Media, Kits, Others), and Services. Based on application, the market is segmented into Drug Development, Regenerative Medicine, Toxicity Testing, Tissue Engineering, and Others. Based on end-user, the market is segmented into Research & Academic Institutes, Biotechnology & Pharmaceutical Companies, and Hospitals & Clinics. Based on region, the market is segmented into North America, Europe, Asia Pacific, Middle East & Africa, and Latin America.

Drivers of the Global Induced Pluripotent Stem Cells Production Market

A significant driving force in the global pluripotent stem cell (iPSC) manufacturing market is the ongoing advancements in regenerative medicine. iPSCs offer substantial potential for tailoring effective therapies across various medical conditions, prompting substantial investments in research and development. This advancement propels market expansion through broadening the range of iPSC applications, offering novel treatment avenues, and drawing investments from pharmaceutical firms and healthcare institutions.

Restraints in the Global Induced Pluripotent Stem Cells Production Market

One significant obstacle in the global iPSC production market stems from ethical and regulatory hurdles. Issues surrounding the use of human-derived materials and the potential for iPSC technology misuse have led to the implementation of strict regulations in certain regions. These challenges may impede research endeavors, increase compliance costs, and generate market uncertainty, thereby affecting the pace of iPSC adoption and commercialization.

Market Trends of the Global Induced Pluripotent Stem Cells Production Market

One significant trend in the global induced pluripotent stem cell (iPSC) manufacturing market is the growing utilization of iPSCs for disease modeling, with researchers and pharmaceutical companies employing iPSC technology to generate disease-specific cell lines. This approach enables more precise and personalized modeling of a range of diseases, including genetic disorders, neurodegenerative conditions, and cardiovascular ailments. Such advancements facilitate drug discovery and development while also fostering the development of targeted and efficient therapeutic strategies, thereby influencing the trajectory of precision medicine in the future.

Introduction

Objectives of the Study
Definitions
Market Scope

Research Methodology

Information Procurement
Secondary & Primary Data Sources
Market Size Estimation
Market Assumptions & Limitations

Executive Summary

Market Overview Outlook
Supply Demand Trend Analysis
Segmental Opportunity Analysis

Market Dynamics & Outlook

Market Dynamics
- Drivers
- Opportunities
- Restraints
- Challenges
Porters Analysis
- Competitive rivalry
- Threat of Substitute Products
- Bargaining Power of Buyers
- Threat of New Entrants
- Bargaining Power of Suppliers

Key Market Insights

Technology Analysis
Patent Analysis
Ecosystem of the Market
Value Chain Analysis
Regulatory Landscape
Innovation Matrix
Top Investment Analysis
Key Success Factor
Degree of Competition

Induced Pluripotent Stem Cells Production Market by Cell Type

Market Overview
Hepatocytes
Fibroblasts
Keratinocytes
Neurons
Others

Induced Pluripotent Stem Cells Production Market by Process

Market Overview
Manual iPSC Production Process
Automated iPSC Production Process

Induced Pluripotent Stem Cells Production Market by Workflow

Market Overview
Reprogramming, Cell Culture
Cell Characterization/Analysis
Engineering
Others

Induced Pluripotent Stem Cells Production Market by Product

Market Overview
Instruments/ Devices
Automated Platforms
Consumables & Kits
- Media
- Kits
- Others
Services

Induced Pluripotent Stem Cells Production Market by Application

Market Overview
Drug Development
Regenerative Medicine
Toxicity Testing
Tissue Engineering
Others

Induced Pluripotent Stem Cells Production Market by End-user

Market Overview
Research & Academic Institutes
Biotechnology & Pharmaceutical Companies
Hospitals & Clinics

Market Size by Region

Market Overview
North America
- USA
- Canada
Europe
- Germany
- Spain
- France
- UK
- Italy
- Rest of Europe
Asia Pacific
- China
- India
- Japan
- South Korea
- Rest of Asia-Pacific
Latin America
- Brazil
- Rest of Latin America
Middle East & Africa (MEA)
- GCC Countries
- South Africa
- Rest of MEA

Competitive Landscape

Top 5 Player Comparison
Market Positioning of Key Players, 2023
Strategies Adopted by Key Market Players
Recent Activities in the Market
Key Companies Market Share (%), 2023

Key Company Profiles

Axl Bioscience Ltd. (UK)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Cynata Therapeutics Limited (UK)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Evotec SE (Germany)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Fate Therapeutics, Inc. (US)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
FUJIFILM Cellular Dynamics, Inc. (US)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Ncardia (Belgium)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Pluricell Biotech (Spain)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
REPROCELL USA, Inc. (US)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Sumitomo Dainippon Pharma Co., Ltd. (Japan)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Takara Bio, Inc. (Japan)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Thermo Fisher Scientific, Inc. (US)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
ViaCyte, Inc. (US)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments

人工多能性幹細胞製造の市場規模、シェア、成長分析、細胞タイプ別、プロセス別、ワークフロー別、製品タイプ別、用途別、エンドユーザー別- 産業予測、2024-2031年

Induced Pluripotent Stem Cells Production Market Size, Share, Growth Analysis, By Cell type, By Process, By Workflow, By Product, By Application, By End-user - Industry Forecast 2024-2031

目次

イントロダクション

調査手法

エグゼクティブサマリー

市場力学と見通し

主な市場の考察

細胞タイプ別人工多能性幹細胞製造市場

プロセス別人工多能性幹細胞製造市場

ワークフロー別人工多能性幹細胞製造市場

製品別人工多能性幹細胞製造市場

用途別人工多能性幹細胞製造市場

エンドユーザー別人工多能性幹細胞製造市場

地域別市場規模